Instruments for customers in biopharma and academia
Axion at a glance & key developments in 2025
Axion Biosystems (Axion) is a global life science tools business headquartered in the US that develops, produces, and markets BEA (Bioelectronic Assay) and live-cell imaging instruments for customers in biopharma and academia. Axion’s products enable scientists to understand cell function in real-time, enabling research and the development of new therapies across various pharmaceutical segments.
In 2025, Axion achieved significant bottom-line improvement alongside continued growth, driven by strong system sales and momentum in expanding its installed base. In addition, Axion acquired CytoTronics, adding a critical technology to the platform (note that the transaction closed in early 2026).
- Year acquired
- 2021
- Revenue
- EUR 24m
- Location
- United States
- Employees
- 114
- Website
- https://www.axionbiosystems.com/
- Investment theme
- Changing Demographics
- Contact
- mehdi.lahlou@summaequity.com
- SDG alignment
3, 9
What are the challenges Axion addresses
-
#1
neurological conditions are the leading cause of ill health and disability worldwide and there are no treatments available to cure
-
90%
of drugs that pass through preclinical studies fail to meet the efficacy or safety margins required in subsequent trials
-
Who is impacted?
Researchers in academia and biopharma and patients are impacted by Axion’s life science research tools. Scientists benefit from improved insights into cell function, while patients benefit indirectly through research and development activities informing future therapeutic innovation.
-
Contribution
Axion contributes to Summa’s theory of change by enabling more effective preclinical research through bioelectronic assay and live-cell imaging instruments. Its tools support better biological understanding and data generation across drug discovery and development workflows.
-
Risks to impact
Key risks to impact include limited adoption, inappropriate experimental use, or weak translation of research findings into clinical development, which may reduce the downstream relevance of insights generated using Axion’s technologies.